Sutro Biopharma: Sutro Biopharma to Highlight its Next-Generation Exatecan and Dual-Payload ADC Programs in Presentations at AACR 2025

SOUTH SAN FRANCISCO, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ:STRO), an oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) Annual Meeting, taking place April 25-30 in Chicago, IL. The presentations will cover preclinical activity and safety data for STRO-004, the Company's novel exatecan Tissue Factor ADC, as well as showcase the unique advantages of Sutro's XpressCF+® platform in enabling precise and efficient development of dual-payload ADCs."We are excited to share our progress advancing our next-generation ADC pipeline at AACR," said Jane Chung, Sutro's Chief Executive Officer. "In preclinical studies, STRO-004 consistently demonstrated potent, dose-dependent anti-tumor activity and a favorable safety profile across all tested doses. Of note, STRO-004, after only a single dose, achieved promising overall response and disease control rates in Tissue Factor-positive patient-derived xenograft models spanning multiple cancer types. We look forward to continuing to investigate the full potential of STRO-004, as we complete IND-enabling studies and prepare to initiate a first-in-human trial later this year."Ms. Chung continued: "Also, as presented at AACR, our XpressCF+® cell-free platform is uniquely capable of creating revolutionary dual-payload ADCs-differentiated by higher drug-to-antibody ratios, fully site-selective conjugation of two linker payloads and a validated, cell-free ADC manufacturing process. We are excited to showcase these and other key features of our platform, which enable our ADC candidates to overcome limitations of conventional ADCs and the challenges of targeting complex disease biology. These presentations further reinforce our technology leadership and our highly ...Full story available on Benzinga.com